Skip to main content

Table 1 Summary statistics describing data variables of the original study

From: A population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: a study of HIV-infected Zimbabwean adolescents

Variable Response
Length of hair (cm), median (range) 1 (0.5–1.5)
Hair weight (grams), mean (Standard Deviation; Range) 2.0 (0.15; 1.76–2.28)
Samples Below limit of quantification
 Atazanavir 18 (18)
 Ritonavir 12 (12)
Drug regimen: recruitment + follow-up, n (%)
 Tenofovir/Lamivudine/Atazanavir-ritonavir 75 (82)
 Abacavir/Didanosine /Atazanavir-ritonavir 6 (7)
 Zidovidine/Lamivudine/Atazanavir-ritonavir 6 (7)
 Abacavir/Lamivudine/Atazanavir-ritonavir 3 (3)
 Tenofovir/ Emtricitabine /Atazanavir-ritonavir 2 (2)
Body mass index-for-age, n (%)
 Normal 25 (54)
 Overweight 7 (15)
 Thinness 14 (30)
Age (years), mean (Standard Deviation; Range) 15.8 (1.8; 11–18)
Gender, n (%)
 Female 27 (54)
Caregiver, n (%)
 Parent 10 (20)
 Grandparent 20 (40)
 Sibling 5 (10)
 Aunt/uncle 15 (30)
Level of education, n (%)
 Secondary school 39 (89)
 Primary school 8 (9)
 Dropped 1 (2)
WHO disease progression stage, n (%)
 Early 16 (32)
 Late 34 (68)
Adherence by visual inspection of analogue scale, mean (Standard Deviation; Range) 84.2 (18.1; 30–100)
Atazanavir concentration (ng/mg), mean (Standard Deviation; Range) 2.5 (2.0; 0.07–8.65)
Ritonavir concentration (ng/mg), mean (Standard Deviation; Range) 0.5 (0.4; 0.01–1.39)